Bryan F Cox

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11813800/publications.pdf

Version: 2024-02-01

53 papers	2,353 citations	236925 25 h-index	206112 48 g-index
53 all docs	53 docs citations	53 times ranked	3091 citing authors

#	Article	IF	Citations
1	ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models. Clinical Cancer Research, 2007, 13, 2728-2737.	7.0	723
2	The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block. Journal of Cardiovascular Pharmacology, 2004, 43, 369-379.	1.9	177
3	The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis. Journal of Cardiovascular Pharmacology, 2001, 37, 607-618.	1.9	159
4	The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. Journal of Pharmacological and Toxicological Methods, 2004, 50, 187-199.	0.7	108
5	Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety. Toxicologic Pathology, 2006, 34, 81-90.	1.8	94
6	Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks. Molecular Cancer Research, 2008, 6, 1621-1629.	3.4	73
7	Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O₂consumption in dogs. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H238-H248.	3.2	57
8	Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. Journal of Molecular and Cellular Cardiology, 2004, 36, 151-160.	1.9	54
9	Diacylglycerol Acyltransferase 1 Inhibition Lowers Serum Triglycerides in the Zucker Fatty Rat and the Hyperlipidemic Hamster. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 526-531.	2.5	49
10	Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemotherapy and Pharmacology, 2004, 54, 273-81.	2.3	45
11	Dopamine D, but not D receptor agonists are emetogenic in ferrets. Pharmacology Biochemistry and Behavior, 2005, 81, 211-219.	2.9	43
12	Postischemic Administration of CGX-1051, a Peptide from Cone Snail Venom, Reduces Infarct Size in Both Rat and Dog Models of Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2005, 46, 141-146.	1.9	42
13	Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: Relevance as a potential biomarker for detecting drug-induced emesis. NeuroImage, 2006, 33, 1152-1160.	4.2	42
14	Electrophysiologic characterization of a novel hERG channel activator. Biochemical Pharmacology, 2009, 77, 1383-1390.	4.4	42
15	In Vitro Preclinical Cardiac Assessment of Tolterodine and Terodiline: Multiple Factors Predict the Clinical Experience. Journal of Cardiovascular Pharmacology, 2006, 48, 199-206.	1.9	39
16	ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats. Journal of Cardiovascular Pharmacology, 2009, 53, 173-178.	1.9	39
17	Evaluation of tissue perfusion in a rat model of hind-limb muscle ischemia using dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2002, 16, 277-283.	3.4	38
18	Block of hERG channel by ziprasidone: Biophysical properties and molecular determinants. Biochemical Pharmacology, 2006, 71, 278-286.	4.4	37

#	Article	IF	Citations
19	Functional consequences of methionine oxidation of hERG potassium channels. Biochemical Pharmacology, 2007, 74, 702-711.	4.4	36
20	ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anti-Cancer Drugs, 2009, 20, 483-492.	1.4	33
21	Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 837-841.	1.9	32
22	Identification and Preliminary Characterization of a Potent, Safe, and Orally Efficacious Inhibitor of Acyl-CoA:Diacylglycerol Acyltransferase 1. Journal of Medicinal Chemistry, 2012, 55, 1751-1757.	6.4	31
23	In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. European Journal of Pharmacology, 2010, 637, 155-161.	3.5	29
24	Hypertension induced by blockade of ETB receptors in conscious nonhuman primates: role of ETAreceptors. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1555-H1561.	3.2	28
25	Systemic Activation of the Calcium Sensing Receptor Produces Acute Effects on Vascular Tone and Circulatory Function in Uremic and Normal Rats: Focus on Central versus Peripheral Control of Vascular Tone and Blood Pressure by Cinacalcet. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 217-226.	2.5	26
26	Pharmacological MRI in awake rats predicts selective binding of Î±₄Î²₂ nicotinic receptors. Synapse, 2008, 62, 159-168.	1.2	24
27	Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H2554-H2559.	3.2	20
28	Importance of Species Selection in Arrythmogenic Models of Q-T Interval Prolongation. Antimicrobial Agents and Chemotherapy, 2002, 46, 938-939.	3.2	18
29	Differential effects of the adenosine A1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Research, 1999, 840, 75-83.	2.2	17
30	Cardiovascular Effects of Torcetrapib in Conscious and Pentobarbital-anesthetized Dogs. Journal of Cardiovascular Pharmacology, 2009, 54, 543-551.	1.9	16
31	Chapter 6 Differential regulation of sympathetic nerve activity by lateral and medial subregions of the rostral ventral medulla. Progress in Brain Research, 1989, 81, 99-103.	1.4	14
32	(â€“)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a Novel ATP-Sensitive Potassium Channel Opener: Hemodynamic Comparison to ZD-6169, WAY-133537, and Nifedipine in the Anesthetized Canine. Journal of Cardiovascular Pharmacology, 2004, 44, 137-147.	1.9	14
33	Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward. Current Opinion in Chemical Biology, 2005, 9, 392-399.	6.1	14
34	ALTERING EXTRACELLULAR POTASSIUM CONCENTRATION DOES NOT MODULATE DRUG BLOCK OF HUMAN ETHER-A-GO-GO-RELATED GENE (hERG) CHANNELS. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1059-1065.	1.9	13
35	Pharmacological characterization of AMP 579, a novel adenosine A1/A2 receptor agonist and cardioprotective. Drug Development Research, 1998, 45, 30-43.	2.9	12
36	Endothelin and ETA receptors in long-term arterial pressure homeostasis in conscious nonhuman primates. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R1701-R1706.	1.8	11

#	Article	IF	Citations
37	Hydroxypropyl Î²-Cyclodextrins: A Misleading Vehicle for the In Vitro hERG Current Assay. Journal of Cardiovascular Pharmacology, 2007, 49, 269-274.	1.9	11
38	The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and d, l-sotalol. Journal of Pharmacological and Toxicological Methods, 2007, 56, 11-17.	0.7	11
39	Preischemic and Postischemic Administration of AEOL10113 Reduces Infarct Size in a Rat Model of Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2003, 41, 714-719.	1.9	10
40	Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers. Life Sciences, 2012, 90, 607-611.	4.3	10
41	K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats. Life Sciences, 2003, 72, 1931-1941.	4.3	9
42	Evidence for two Functionally Distinct Vasomotor Subregions of Rostral Ventral Medulla. Clinical and Experimental Hypertension, 1988, 10, 11-18.	0.3	8
43	Regional Hemodynamic Dose-Response of Lemakalim and Glybenclamide in Anesthetized Rats. Journal of Cardiovascular Pharmacology, 1997, 29, 49-56.	1.9	8
44	Evidence for Vasoconstriction Mediated by the Endothelin-B Receptor in Domestic Swine. Journal of Cardiovascular Pharmacology, 2000, 35, 838-844.	1.9	8
45	Pharmacological Characterization of the Novel Dihydropyridine Potassium Channel Opener, (9R)-9-(3-Iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the Regulation of Cardiovascular Function in Conscious and Anesthetized Beagle Dogs. Journal of Cardiovascular Pharmacology, 2005, 46, 232-240.	1.9	6
46	A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current. Biochemical Pharmacology, 2010, 80, 1000-1006.	4.4	6
47	Ventricular rate adaptation: A novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds. Journal of Pharmacological and Toxicological Methods, 2011, 64, 68-73.	0.7	6
48	Negative Inotropic Effect of a CB2 Agonist A-955840 in Isolated Rabbit Ventricular Myocytes is Independent of CB1 and CB2 Receptors. Current Drug Safety, 2011, 6, 277-284.	0.6	6
49	Tonic Control of Arterial Pressure and Regional Hemodynamics by Supra-Medullary Sites. Clinical and Experimental Hypertension, 1991, 13, 197-218.	0.3	3
50	Tumourâ€selective antivascular effects of the novel antiâ€mitotic compound Aâ€318315: An in vivo rat regional haemodynamic study. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 636-640.	1.9	2
51	ABTâ€127, a novel Dopamine D3 Receptor Antagonist: Cardiovascular Profile in the Anesthetized Dog. FASEB Journal, 2006, 20, A1109.	0.5	0
52	Comprehensive Hemodynamic Assessment of Levosimendan and its Two Metabolites (ORâ€1896 and) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.5	0
53	Hemodynamic Effects of Levosimendan and its Two Metabolites (ORâ€1896 and ORâ€1855) in Anesthetized Rats: Comparison to Dobutamine and Milrinone. FASEB Journal, 2007, 21, A798.	0.5	0